Thoratec completes enrollment in Bridge-to-Transplantation arm of HeartMate trial

By Elaine Rigoli

Tampa, Fla., May 31 - Thoratec Corp. said it has completed enrollment in the Bridge-to-Transplantation (BTT) arm of its HeartMate 2 pivotal trial by implanting 133 patients.

"This marks an important milestone in our HeartMate 2 program, as we have now enrolled the number of patients called for in the original trial design and we achieved this goal within 15 months of the trial's initiation. We continue to be encouraged by the positive patient experience in the trial as reported in recent data presentations at leading professional medical meetings," president and chief executive officer Gary F. Burbach said in a news release.

"At the same time, we are pleased that BTT patients will be able to continue to receive the device under our Continued Access Protocol and we expect that centers will begin enrolling these new patients within the next few days," he added.

Pleasanton, Calif.-based Thoratec develops hemodynamic restoration therapy-developing products to treat cardiovascular disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.